更新于：2024-11-04
Hydrocortisone Sodium Succinate
氢化可的松琥珀酸钠
更新于：2024-11-04
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构
分子式C25H34NaO8 |
InChIKeyLGKJVUKNTHOZJH-CODXZCKSSA-N |
CAS号125-04-2 |
关联
32
项与 氢化可的松琥珀酸钠 相关的临床试验A Phase 1 Study of GRN163L (Imetelstat) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia That is in Second or Greater Relapse or That is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or is Refractory to Relapse Therapy
A Phase 2 Study of Revumenib (SNDX-5613) in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia
An Open-label, Single-arm, Single-center Study Evaluating the Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
100 项与 氢化可的松琥珀酸钠 相关的临床结果
登录后查看更多信息
100 项与 氢化可的松琥珀酸钠 相关的转化医学
登录后查看更多信息
100 项与 氢化可的松琥珀酸钠 相关的专利（医药）
登录后查看更多信息
750
项与 氢化可的松琥珀酸钠 相关的文献（医药）2024-09-01STEROIDS
Biotransformation of hydrocortisone succinate with whole cell cultures of Monascus purpureus and Cunninghamella echinulata
Article
作者: Aziz, Zainab ; Rashid Khan, Afsana ; Sheema ; Rahman Khan, Abdur ; Iqbal, Amir ; Zafar, Salman
Hydrocortisone succinate (1) is a synthetic anti-inflammatory drug and key intermediate in the synthesis of other steroidal drugs. This work is based on the fungal biotransformation of 1, using Monascus purpureus and Cunninghamella echinulata strains. Comopound 1 was transformed into four metabolites, identified as hydrocortisone (2), 11β-hydroxyandrost-4-en-3,17-dione (3), Δ1-cortienic acid (4), and hydrocortisone-17-succinate (5), obtained through side chain cleavage, hydrolysis, dehydrogenation, and oxidation reactions. These compounds have previously been synthesized either chemically or enzymatically from different precursors. Though this is not the first report on the biotransformation of 1, but it obviously is a first, where the biotransformed products of compound 1 have been characterized structurally with the help of modern spectroscopic techniques. It is noteworthy that these products have already shown biological potential, however a more thorough investigation of the anti-inflammatory properties of these metabolites would be of high value. These results not only emphasize upon the immense potential of biotransformation in catalysis of reactions, otherwise not-achievable chemically, but also holds promise for the development of novel anti-inflammatory compounds.
2023-08-01Annales d'endocrinologie
Congenital adrenal hyperplasia: New biomarkers and adult treatments
Review
作者: Tabarin, Antoine ; Dreves, Bleuenn ; Reznik, Yves
Congenital adrenal hyperplasia (CAH) is a genetic disease caused by an enzyme deficiency interrupting adrenal steroidogenesis. It most frequently involves 21-hydroxylase, which induces adrenal insufficiency with hyperandrogenism. Restoring hormonal balance is difficult with glucocorticoids, which are the gold-standard treatment. Strict normalization of conventional biomarkers (17-hydroxyprogesterone and delta-4 androstenedione) is often obtained at the cost of iatrogenic hypercortisolism. Optimizing the management of these patients first involves using more specific biomarkers of adrenal steroidogenesis in difficult situations, and secondly using therapeutics targeting the induced hypothalamic-pituitary-adrenal axis disorder. 11-oxygenated androgens are candidates for biochemical monitoring of Congenital adrenal hyperplasia (CAH), in particular 11-ketotestosterone. Numerous new therapeutic agents are currently being explored, the prime goal being to reduce glucocorticoid exposure, as no strategy can fully replace it at present. They can be divided into 3 categories. The first includes "more physiological" hydrocortisone administration (modified-release hydrocortisone and continuous subcutaneous infusion of hydrocortisone hemisuccinate); the second includes corticotropin releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) receptor antagonists and anti-ACTH antibodies; and the third includes steroidogenesis inhibitors. Finally, experiments on gene and cell therapies suggest the possibility of lasting remission or even cure in the future.
2023-06-21Cell & bioscience
The development of an anti-cancer peptide M1-21 targeting transcription factor FOXM1.
Article
作者: Yuan, Jie ; Yu, Li ; Ouyang, Min ; Pei, Chaozhu ; Zhang, Zhenwang ; Chen, Yan ; Tan, Yongjun ; Huang, Xiaoqin ; Bu, Huitong ; Cheng, Haojie
BACKGROUND:
Transcription factor FOXM1 is a potential target for anti-cancer drug development. An interfering peptide M1-21, targeting FOXM1 and FOXM1-interacting proteins, is developed and its anti-cancer efficacy is evaluated.
METHODS:
FOXM1 C-terminus-binding peptides are screened by in silico protocols from the peptide library of FOXM1 (1-138aa) and confirmed by cellular experiments. The selected peptide is synthesized into its D-retro-inverso (DRI) form by fusing a TAT cell-penetrating sequence. Anti-cancer activities are evaluated in vitro and in vivo with tumor-grafted nude mice, spontaneous breast cancer mice, and wild-type metastasis-tracing mice. Anti-cancer mechanisms are analyzed. Distribution and safety profiles in mice are evaluated.
RESULTS:
With improved stability and cell inhibitory activity compared to the parent peptide, M1-21 binds to multiple regions of FOXM1 and interferes with protein-protein interactions between FOXM1 and its various known partner proteins, including PLK1, LIN9 and B-MYB of the MuvB complex, and β-catenin. Consequently, M1-21 inhibits FOXM1-related transcriptional activities and FOXM1-mediated nuclear importation of β-catenin and β-catenin transcriptional activities. M1-21 inhibits multiple types of cancer (20 µM in vitro or 30 mg/kg in vivo) by preventing proliferation, migration, and WNT signaling. Distribution and safety profiles of M1-21 are favorable (broad distribution and > 15 h stability in mice) and the tested non-severely toxic dose reaches 200 mg/kg in mice. M1-21 also has low hemolytic toxicity and immunogenicity in mice.
CONCLUSIONS:
M1-21 is a promising interfering peptide targeting FOXM1 for the development of anti-cancer drugs.
100 项与 氢化可的松琥珀酸钠 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 哮喘 | 日本 | 1968-04-23 | |
| 创伤性休克 | 日本 | 1968-04-23 | |
| 沃-弗综合征 | 日本 | 1968-04-23 | |
| 过敏 | 美国 | 1955-04-27 | |
| 内分泌系统疾病 | 美国 | 1955-04-27 | |
| 眼部疾病 | 美国 | 1955-04-27 | |
| 血液疾病 | 美国 | 1955-04-27 | |
| 肾脏疾病 | 美国 | 1955-04-27 | |
| 肿瘤 | 美国 | 1955-04-27 | |
| 呼吸系统疾病 | 美国 | 1955-04-27 | |
| 风湿性疾病 | 美国 | 1955-04-27 | |
| 皮肤疾病 | 美国 | 1955-04-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 78 | HC+cyclophosphamide+PEG+leucovorin calcium+thioguanine+6-MP+dexamethasone+MTX+vincristine sulfate+daunorubicin hydrochloride+AZACITIDINE (AZA)+ARA-C (KMT2A-Rearranged) | 鹽夢蓋憲艱醖蓋鹽蓋廠(艱構窪簾獵網廠醖膚鑰) = 廠製齋憲餘壓糧壓膚膚 鹽窪製鬱襯選壓觸簾顧 (艱鏇觸鬱齋鬱遞鬱窪醖, 遞鏇壓築憲繭鹽簾糧糧 ~ 憲鏇襯襯襯餘蓋遞製醖) 更多 | - | 2021-10-26 | ||
cytarabine (ARA-C)+prednisolone+dexamethasone+vincristine sulfate+Methotrexate+daunorubicin hydrochloride (KMT2A-Germline) | 鬱鏇淵遞網艱選積夢構(網鬱窪衊鬱選糧醖顧範) = 壓鹹獵遞壓襯艱醖鏇窪 襯積鑰網壓壓窪餘艱壓 (繭遞選膚鑰範夢築壓艱, 繭鑰鹹選鏇憲膚淵構膚 ~ 蓋醖淵製網觸獵淵壓鏇) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用